Andrew T. Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrew T. Yan has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Shaun G. Goodman
6 shared publicationsRaymond T. Yan
5 shared publicationsAnatoly Langer
4 shared publicationsDavid H. Fitchett
4 shared publicationsThao Huynh
3 shared publicationsAlan J. Bagnall
Department of Cardiology, The Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, UK
2 shared publications
Latest Publications
- Open Access
- 1 September 2010
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 3 (5) , 530-537
Optimal Medical Therapy for Non–ST-Segment–Elevation Acute Coronary Syndromes
Background— Acute coronary syndrome (ACS) patients in the highest risk categories are least likely to receive evidence-based treatments (EBTs). We sought to determine why physicians do not prescribe EBTs for patients with non–ST-segment–elevation ACSs and the factors determining use of these treatments after 1 year. Methods and Results— One thousand nine hundred fifty-six non–ST-segment-elevation ACS patients were enrolled in the prospective, multicenter Canadian ACS registry II between October 2002 and December 2003. Each patient's physician gave reasons why guideline-indicated medication(s) was not prescribed during hospitalization. Medication use and reason(s) for discontinuation after 1 year were obtained by telephone interview of the patients. The commonest reason for not prescribing EBTs was “not high-enough risk” or “no evidence/guidelines to support use.” However, Global Registry of Acute Coronary Events scores of patients not treated for this reason were often similar to or higher than those of patients prescribed such treatment. After 1 year, 77% of patients not on optimal ACS treatment at discharge remained without optimal treatment, and overall antiplatelet, β-blocker, and angiotensin-converting enzyme inhibitor use declined. Approximately one third of patients not taking EBTs had stopped their medication without instruction from their doctor. Conclusions— Nonprovision of EBTs may be due to subjective underestimation of patient risk and hence, likely treatment benefit. Oversights in care delivery were also apparent. Objective risk stratification, combined with efforts to ensure provision and adherence to EBTs, should be encouraged.
- 1 September 2010
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 3 (5) , 530-537
Open AccessOptimal Medical Therapy for Non–ST-Segment–Elevation Acute Coronary Syndromes
Background— Acute coronary syndrome (ACS) patients in the highest risk categories are least likely to receive evidence-based treatments (EBTs). We sought to determine why physicians do not prescribe EBTs for patients with non–ST-segment–elevation ACSs and the factors determining use of these treatments after 1 year. Methods and Results— One thousand nine hundred fifty-six non–ST-segment-elevation ACS patients were enrolled in the prospective, multicenter Canadian ACS registry II between October 2002 and December 2003. Each patient's physician gave reasons why guideline-indicated medication(s) was not prescribed during hospitalization. Medication use and reason(s) for discontinuation after 1 year were obtained by telephone interview of the patients. The commonest reason for not prescribing EBTs was “not high-enough risk” or “no evidence/guidelines to support use.” However, Global Registry of Acute Coronary Events scores of patients not treated for this reason were often similar to or higher than those of patients prescribed such treatment. After 1 year, 77% of patients not on optimal ACS treatment at discharge remained without optimal treatment, and overall antiplatelet, β-blocker, and angiotensin-converting enzyme inhibitor use declined. Approximately one third of patients not taking EBTs had stopped their medication without instruction from their doctor. Conclusions— Nonprovision of EBTs may be due to subjective underestimation of patient risk and hence, likely treatment benefit. Oversights in care delivery were also apparent. Objective risk stratification, combined with efforts to ensure provision and adherence to EBTs, should be encouraged.
- 1 April 2010
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 26 (4) , e134-e135
Cardiac magnetic resonance imaging of a large prolapsing left atrial myxoma causing pulmonary hypertension and syncope
- 1 April 2010
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 26 (4) , e134-e135
Cardiac magnetic resonance imaging of a large prolapsing left atrial myxoma causing pulmonary hypertension and syncope
- 1 November 2009
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 25 (11) , e370-e376
Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification
- 1 November 2009
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 25 (11) , e370-e376
Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification
- Open Access
- 23 February 2009
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 169 (4) , 372-378
Understanding Physicians' Risk Stratification of Acute Coronary Syndromes
Because non-ST-segment elevation acute coronary syndromes (ACSs) encompass a broad spectrum of clinical conditions, accurate risk stratification is a critical step in optimal patient care.1,2 The overriding principle is to selectively target more intensive medical and interventional treatment toward high-risk patients.
- 23 February 2009
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 169 (4) , 372-378
Open AccessUnderstanding Physicians' Risk Stratification of Acute Coronary Syndromes
Because non-ST-segment elevation acute coronary syndromes (ACSs) encompass a broad spectrum of clinical conditions, accurate risk stratification is a critical step in optimal patient care.1,2 The overriding principle is to selectively target more intensive medical and interventional treatment toward high-risk patients.
- Open Access
- 4 February 2009
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (5) , 549-557
Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction
To examine: (i) the temporal changes in the management pattern; (ii) the reasons for any treatment disparities; (iii) the relationship between invasive treatment and outcome, among acute coronary syndrome (ACS) patients with vs. without kidney dysfunction. Canadian ACS I, ACS II registries and Global Registry of Acute Coronary Events (GRACE) were prospective, multi-centre, observational studies of patients with ACS. From 1999 to 2007, non-ST elevation (NSTE) ACS patients were recruited in ACS I (n = 3295; 1999–2001), ACS II (n = 1956; 2002–2003), and GRACE (n = 6491; 2004–2007) in Canada. Using the four-variable Modified Diet in Renal Disease equation, we stratified the study population (n = 11 377) into three groups based on their estimated glomerular filtration rate (eGFR), and examined their treatment and outcome. While in-hospital use of coronary angiography and revascularization increased over time in all groups (P < 0.001), patients with kidney dysfunction were less likely to undergo invasive management (P < 0.001). Unadjusted 1 year mortality was lower among patients receiving in-hospital coronary angiography within all eGFR categories (≥60 mL/min/1.73 m2: 2.5 vs. 7.6%, P < 0.001; 30–59 mL/min/1.73 m2: 8.0 vs. 14.6%, P < 0.001; 2: 27.5 vs. 41.5%, P = 0.043). In-hospital revascularization was independently associated with lower 1-year mortality (adjusted OR = 0.52, 95% CI 0.36–0.77, P = 0.001), irrespective of eGFR (P for heterogeneity = 0.39). Underestimation of patient risk was the most common barrier to an invasive treatment strategy. Despite temporal increases in invasive management of NSTE‐ACS, patients with kidney dysfunction are more commonly treated conservatively, with an associated worse outcome. In-hospital revascularization was independently associated with improved survival, irrespective of eGFR. Randomized controlled trials involving patients with kidney dysfunction are needed to confirm whether more aggressive treatment will improve their poor outcome.
- 4 February 2009
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (5) , 549-557
Open AccessTemporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction
To examine: (i) the temporal changes in the management pattern; (ii) the reasons for any treatment disparities; (iii) the relationship between invasive treatment and outcome, among acute coronary syndrome (ACS) patients with vs. without kidney dysfunction. Canadian ACS I, ACS II registries and Global Registry of Acute Coronary Events (GRACE) were prospective, multi-centre, observational studies of patients with ACS. From 1999 to 2007, non-ST elevation (NSTE) ACS patients were recruited in ACS I (n = 3295; 1999–2001), ACS II (n = 1956; 2002–2003), and GRACE (n = 6491; 2004–2007) in Canada. Using the four-variable Modified Diet in Renal Disease equation, we stratified the study population (n = 11 377) into three groups based on their estimated glomerular filtration rate (eGFR), and examined their treatment and outcome. While in-hospital use of coronary angiography and revascularization increased over time in all groups (P < 0.001), patients with kidney dysfunction were less likely to undergo invasive management (P < 0.001). Unadjusted 1 year mortality was lower among patients receiving in-hospital coronary angiography within all eGFR categories (≥60 mL/min/1.73 m2: 2.5 vs. 7.6%, P < 0.001; 30–59 mL/min/1.73 m2: 8.0 vs. 14.6%, P < 0.001; 2: 27.5 vs. 41.5%, P = 0.043). In-hospital revascularization was independently associated with lower 1-year mortality (adjusted OR = 0.52, 95% CI 0.36–0.77, P = 0.001), irrespective of eGFR (P for heterogeneity = 0.39). Underestimation of patient risk was the most common barrier to an invasive treatment strategy. Despite temporal increases in invasive management of NSTE‐ACS, patients with kidney dysfunction are more commonly treated conservatively, with an associated worse outcome. In-hospital revascularization was independently associated with improved survival, irrespective of eGFR. Randomized controlled trials involving patients with kidney dysfunction are needed to confirm whether more aggressive treatment will improve their poor outcome.
- 1 December 2007
- Published by Elsevier in American Heart Journal
- Vol. 154 (6) , 1108-1115
Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome
- 1 December 2007
- Published by Elsevier in American Heart Journal
- Vol. 154 (6) , 1108-1115
Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome